⚠️ Mora 2004 (10.1016/j.semcdb.2003.12.022) is closed-access and could not be verified against the full PDF. Claims attributed solely to ¹ (PIF-pocket mechanism details, RSK contact-mode description, substrate catalog completeness) are unverified. no-fulltext-access

PDK1 (PDPK1)

Disambiguation: This page covers 3-phosphoinositide-dependent protein kinase 1 (gene: PDPK1; UniProt O15530), the master AGC kinase activator. Do NOT confuse with pyruvate dehydrogenase kinase 1 (gene: PDK1; a mitochondrial metabolic enzyme unrelated to PI3K signaling).

PDK1/PDPK1 is the master serine/threonine kinase that phosphorylates and activates the activation loop (“T-loop”) of AGC-family kinases including PKB, S6K1, RSK, SGK, PKCζ, PKCδ, and PKN. It is constitutively active and achieves substrate selectivity through two distinct docking mechanisms: (1) PIP3-dependent co-recruitment to the plasma membrane for AKT activation; and (2) PIF-pocket binding to the phosphorylated hydrophobic motif of substrates like S6K1. Because PDK1 sits at the convergence of PI3K→AKT and mTORC1→S6K axes, it is a central node in growth factor signaling and insulin-sensitivity circuits relevant to aging.

Identity

UniProt: O15530 (PDPK1_HUMAN) — Swiss-Prot reviewed entry
NCBI Gene: 5170
HGNC symbol: PDPK1 (the gene symbol; “PDK1” is a widely-used protein alias)
Mouse ortholog: Pdpk1 (one-to-one ortholog)
Length: 556 amino acids (canonical isoform)
Expression: Ubiquitous; elevated in diseased lung, liver, colon, and breast tissue vs normal tissue (UniProt O15530)

Domain organization

Domain	Residues (approx.)	Function
N-terminal kinase domain	82–342	Catalytic; phosphorylates substrate T-loops; contains PIF-pocket
PIF-pocket	113–157 (within kinase domain)	Allosteric docking site for substrates bearing a phospho-hydrophobic motif
Linker	343–458	Flexible; may participate in dimerization
C-terminal PH domain	459–550	Binds PIP3/PIP2 at plasma membrane; required for AKT co-recruitment; nuclear localization

The PIF-pocket (PDK1-interacting fragment pocket) is an allosteric groove on the kinase domain that binds the phosphorylated hydrophobic motif (HM) of AGC substrates such as S6K1 (pThr389-HM), PKCζ, and RSK. This docking event positions the substrate’s activation loop for PDK1-mediated phosphorylation ¹.

The PH domain binds PtdIns(3,4,5)P3 (PIP3) generated by PI3K in response to growth factors. For AKT, both PDK1 and AKT possess PH domains that independently bind PIP3, enabling their co-localization at the inner leaflet of the plasma membrane where PDK1 phosphorylates AKT at Thr308 ² ³.

Kinase mechanism: two modes of substrate recruitment

PDK1 is constitutively active — it is phosphorylated on its own activation loop (Ser241, by autophosphorylation) regardless of growth factor stimulation. Selectivity is achieved entirely at the level of substrate recruitment:

Mode 1 — PIP3-dependent (AKT)

PI3K activation by upstream receptor (e.g., IGF-1R, InsR) generates PIP3 at the plasma membrane.
Both PDK1 (via its PH domain) and AKT (via AKT’s PH domain) translocate to PIP3-rich membrane domains.
PDK1 phosphorylates AKT at Thr308 in the kinase domain activation loop ³.
Full AKT activation requires a second phosphorylation at Ser473 by mTORC2 (PDK1-independent).
PTEN terminates the signal by dephosphorylating PIP3 → PIP2.

Mode 2 — PIF-pocket-dependent (S6K1, RSK, SGK, PKCζ)

mTORC1-activated S6K1 is phosphorylated at its C-terminal hydrophobic motif (Thr389).
The phospho-HM of S6K1 docks into the PIF-pocket on PDK1’s kinase domain.
This docking event presents S6K1’s activation loop for PDK1-mediated phosphorylation at Thr229 ⁴.
This mode is PIP3-independent; it integrates mTORC1 activity with PDK1 catalysis.

The two-mode architecture means PDK1 integrates both PI3K/growth-factor signals (Mode 1) and mTORC1/nutrient signals (Mode 2) through a single catalytic subunit ¹.

Key substrates and phosphorylation sites

Substrate	PDK1 phosphorylation site	Function of PDK1 action
AKT/PKB	Thr308 (activation loop)	Full AKT activation; cell survival, glucose uptake
S6K1	Thr229 (activation loop)	Protein synthesis activation; growth
RSK1	Ser221 (N-terminal kinase domain)	ERK pathway effector; growth, translation
RSK2	Ser227 (N-terminal kinase domain)	As above
SGK1	Thr256 (activation loop)	Ion channel regulation; aldosterone response
PKCζ	Thr410 (activation loop)	NF-κB signaling, cell polarity
PKCδ	Thr505 (activation loop)	Apoptotic signaling contexts
PKN/PRK	Thr774 (activation loop)	Cytoskeletal organization

Note: for RSK, PDK1 phosphorylates the N-terminal kinase domain activation loop; RSK must first be primed by ERK phosphorylation of its C-terminal kinase domain. PDK1 does not require the PIF-pocket for RSK — it contacts RSK’s C-terminal domain directly ¹. needs-replication (exact mode for RSK is based primarily on biochemical studies; in-vivo genetic confirmation in mammals is limited).

Key PTMs on PDK1 itself

Ser241 (autophosphorylation) — constitutive activation loop phosphorylation; required for catalytic activity; PDK1 autophosphorylates in cis
Tyr9, Tyr373, Tyr376 — phosphorylated by SRC and by the insulin receptor (INSR); Tyr373/376 phosphorylation is critical for stabilization and full activity (UniProt O15530)
Thr354 — inhibitory phosphorylation by MELK; partially reduces activity
Ser394, Ser398 — inhibitory phosphorylation by MAP3K5 (ASK1); cooperative inhibition with Thr354

In vivo phenotypes: KO and hypomorphic mice

Germline KO (Pdpk1−/−): Embryonic lethal at E9.5 — no PDK1−/− pups were recovered at weaning; embryos were present at expected Mendelian ratios through E9.5 but absent at E10+ ⁵. Embryos at E8.5–E9.5 display severe growth retardation, absent somites, absent forebrain, no branchial arches, and no heart, demonstrating that PDK1 is non-redundantly required for early mammalian development.

Hypomorphic (Pdpk1 ~10–20% normal expression, PDK1−/fl line): Viable, fertile mice that are 40–50% smaller in body weight than PDK1+/fl littermates ⁵. Organ volumes (kidney, pancreas, spleen, adrenal gland) are ~50% reduced, accounted for by reduced cell size rather than reduced cell number. Critically: insulin-stimulated activation of PKB, S6K and RSK is normal in these mice despite the markedly reduced PDK1 levels — the paper concludes that the PDK1 levels sufficient to regulate cell size are insufficient to maximally activate PKB/S6K/RSK, and that PDK1 regulates cell size independently of its role in insulin signaling. The wiki previously stated “improved insulin sensitivity” — this is NOT supported by Lawlor 2002; the paper shows normal (not enhanced) insulin-pathway activation.

Note: a less severe homozygous hypomorphic line (PDK1fl/fl, ~20–33% normal expression) was ~30% smaller.

Dimension	Status	Notes
Pathway conserved in humans?	yes	PDPK1 is universally expressed; AKT Thr308 / S6K1 Thr229 phosphorylation mechanistically identical in humans
Phenotype conserved in humans?	partial	No human PDPK1 hypomorphs studied; reduced cell/organ size with normal insulin signaling is the mouse phenotype; human correlate unknown
Replicated in humans?	no	Direct human genetic evidence lacking needs-human-replication

Aging relevance: The hypomorphic phenotype — reduced somatic growth with normal (not impaired) insulin-stimulated PKB/S6K/RSK activation ⁵ — is structurally reminiscent of small-body-size longevity models, but the mechanism here is cell-size reduction rather than metabolic reprogramming. Importantly, Lawlor 2002 does NOT report improved insulin sensitivity or any longevity phenotype; the aging-relevance inference is indirect, based on the PDK1 node’s position in the IIS/mTOR axes known from other experimental systems. needs-human-replication needs-replication (longevity inference is not tested in Lawlor 2002)

Role in aging and longevity pathways

PDK1 sits at the apex of two of the best-validated longevity-relevant signaling axes:

IIS axis (insulin-igf1 → pi3k-akt-pathway → PDK1 → AKT → FOXO): reduced flux through this axis extends lifespan in worm (daf-2/daf-16), fly (InR/FOXO), and mice (Igf1r heterozygotes). PDK1 is the obligate kinase linking PI3K output to AKT activation.
mTOR/S6K axis (mtor → S6K-pHM → PDK1-PIF-pocket → s6k1 Thr229): S6K1 deletion extends mouse lifespan ~19% in females (Selman 2009 unsourced — cite pending). PDK1 is the direct activator of S6K1’s catalytic loop; constitutive PDK1 activity sustains this growth-promoting axis.

Because PDK1 is constitutively active, its downstream outputs are primarily gated by (a) PIP3 availability (PTEN-regulated) and (b) S6K1 priming by mTORC1. PDK1 itself is not a primary target of caloric restriction or rapamycin; the pathway is shut down upstream (PI3K, mTORC1) or downstream (AKT, S6K1), with PDK1 as the effector relay.

Pathway membership

pi3k-akt-pathway — core kinase; phosphorylates AKT Thr308 downstream of PI3K
insulin-igf1 — essential transducer; bridges receptor-level PIP3 production to AKT activation
mtor — feeds into S6K1 activation via PIF-pocket mode; parallel to mTORC1→S6K1 axis

Key interactors

akt — primary substrate via Mode 1 (PIP3-dependent)
s6k1 — primary substrate via Mode 2 (PIF-pocket)
pi3k — upstream PIP3 producer; determines Mode 1 activity
pten — indirect regulator; PTEN destroys PIP3, dampening PDK1→AKT axis
mtor — indirect regulator of Mode 2 via mTORC1-mediated S6K1 HM phosphorylation

Pharmacology and therapeutic context

PDK1 inhibitors have been explored as anti-cancer agents (since PDK1→AKT is hyperactive in many tumors). Several ATP-competitive inhibitors (OSU-03012, BX795, GSK2334470) are in preclinical or early clinical development for oncology. None are aging-specific therapeutic candidates yet.

PIF-pocket allosteric inhibitors are of interest because they would selectively block Mode 2 (S6K1 activation) without affecting Mode 1 (AKT activation) — potentially allowing pro-longevity S6K1 inhibition without the glucose homeostasis penalties of full AKT suppression. no-mechanism (no PIF-pocket-selective compound has reached in-vivo aging studies as of 2026-05).

Druggability — tier-2 (re-rated 2026-05-08). No PDK1 inhibitor is FDA-approved or in late-stage clinical development for any indication; OSU-03012, BX795, and GSK2334470 are preclinical/early-clinical oncology probes. The earlier tier-1 designation reflected PDK1’s position as the master AGC-kinase activator at the convergence of PI3K→AKT and mTORC1→S6K (two well-validated longevity axes) + the depth of biochemical/structural tractability (PIF-pocket allosteric site is druggable) + the existence of a small-molecule probe class — but the strict Open Targets criterion (Approved Drug = true for an aging indication) does not apply, and pathway centrality does not by itself justify tier-1 in the aging-context convention. Tier-2 (“high-quality probe”) accurately reflects the current state.

Limitations and gaps

needs-human-replication — No human PDPK1 partial-loss variants have been characterized for aging outcomes; the mouse hypomorphic phenotype (reduced cell size with normal insulin-pathway signaling) has no established human correlate.
needs-replication — RSK activation-loop mechanism attribution is primarily biochemical; in-vivo genetic dissection in mammals is limited.
long-term-unknown — PDK1 inhibitor compounds have not been tested in long-term lifespan assays; only tumor-model data exist.
unsourced — S6K1 deletion lifespan extension claim (Selman 2009) needs citation; cite s6k1 page where it is handled.
no-fulltext-access — Mora 2004 (10.1016/j.semcdb.2003.12.022) is closed-access; PIF-pocket docking details, RSK contact-mode, and substrate site completeness attributed to ¹ are unverified against the primary review.
DOI correction confirmed: 10.1093/emboj/15.23.6541 is a non-existent DOI; the correct Alessi 1996 EMBO J DOI is 10.1002/j.1460-2075.1996.tb01045.x — verified against Crossref and the PDF (EMBO J vol. 15, pp. 6541–6551).

Footnotes

mora-2004-pdk1-agc-review · doi:10.1016/j.semcdb.2003.12.022 · review · comprehensive mechanistic review of PDK1 as master AGC kinase regulator; PIF-pocket mechanism; substrate catalog · 820 citations · local PDF: not available (not_oa) no-fulltext-access — claims attributed to this source (PIF-pocket docking detail, RSK contact-mode, substrate site completeness) could not be verified against the primary source ↩ ↩² ↩³ ↩⁴ ↩⁵
alessi-1997-pdk1-characterization · doi:10.1016/s0960-9822(06)00122-9 · in-vitro · original purification (500,000-fold from rabbit skeletal muscle) and characterization of PDK1; PDK1 phosphorylates PKBα at Thr308 only (not Ser473); activates PKBα >30-fold; PtdIns(3,4,5)P3- and PtdIns(3,4)P2-dependent; PDK1 is a 67 kDa protein kinase not inhibited by wortmannin · model: purified enzyme (rabbit skeletal muscle) + recombinant GST-PKBα in 293 cells · 2814 citations · local PDF: verified ↩
alessi-1996-pkb-activation-mechanism · doi:10.1002/j.1460-2075.1996.tb01045.x · in-vitro + in-vivo (L6 myotubes, 293 cells, COS-1 cells) · PKBα phosphorylation at Thr308 and Ser473 both required for full activation; Thr308 = PDK1 site; Ser473 = separate kinase (MAPKAPK2 in vitro, physiological Ser473 kinase unknown at time of publication; now attributed to mTORC2); phosphorylation of both sites abolished by wortmannin; insulin 12-fold activation in L6 myotubes; IGF-1 20- and 50-fold in transfected 293 cells · model: L6 rat myotubes, 293 cells, COS-1 cells · 3017 citations · local PDF: verified ↩ ↩²
pullen-1998-s6k-pdk1-activation · doi:10.1126/science.279.5351.707 · in-vitro + in-vivo (293 cells, overexpression) · PDK1 phosphorylates p70-S6K1 at Thr229 (activation loop); phosphorylation requires prior phosphorylation of p70-S6K1 at Thr389 (hydrophobic motif) to allow access; PDK1 is constitutively active and wortmannin/rapamycin-insensitive; catalytically inactive PDK1-KD blocks insulin-induced S6K activation; note: the term “PIF-pocket” does not appear in this paper — the mechanism was described functionally here; the PIF-pocket framework was named in subsequent work (Biondi 2001, Mora 2004) · model: 293 cells, overexpression · 833 citations · local PDF: verified ↩
lawlor-2002-pdpk1-mice · doi:10.1093/emboj/cdf387 · in-vivo · Pdpk1 null = embryonic lethal E9.5 (recovered through E9.5, absent E10+); hypomorphic PDK1−/fl (~10-20% expression) = viable, fertile, ~40-50% reduced body weight vs littermates, ~50% reduced organ volume (cell-size reduction, not cell-number reduction); insulin-stimulated PKB/S6K/RSK activation is NORMAL (not improved) · model: Mus musculus (chimeric ES cell → mixed C57Black6/Balb/c background) · 323 citations · local PDF: verified ↩ ↩² ↩³

🧬 Aging Wiki

Explorer

pdk1